CD274 and renal cell carcinoma: Although programmed death-ligand 1 (PD-L1) expression in tumors is used to predict the clinical benefits of antiprogrammed cell death protein-1 (PD-1) or PD-L1 immunotherapy in various other malignancies [6,7], it has no role in patients with advanced RCC who are treated with first-line immunotherapy.